What are the side effects of carboplatin and paclitaxel for Endometrial Cancer

Endometrial CancerMay 16, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Side Effects of Carboplatin and Paclitaxel for Endometrial Cancer

Carboplatin and paclitaxel is one of the most commonly used chemotherapy combinations for endometrial cancer, particularly for advanced or recurrent disease. According to the NCCN Guidelines for Uterine Neoplasms, this regimen is a preferred, first-line option because it has a better safety and tolerability profile compared to other chemotherapy combinations, while maintaining similar effectiveness.

Common Side Effects

Blood-Related Effects (Most Common)

  • Neutropenia (low white blood cells) - increases infection risk
  • Thrombocytopenia (low platelets) - increases bleeding/bruising risk
  • Anemia (low red blood cells) - causes fatigue and shortness of breath
  • These typically recover between treatment cycles

Nervous System Effects

  • Peripheral neuropathy (nerve damage in hands/feet) - numbness, tingling, or pain
    • This is one of the more significant side effects to monitor
    • Usually develops gradually during treatment
    • May persist after treatment ends in some patients

Gastrointestinal Effects

  • Nausea and vomiting
  • Loss of appetite
  • Mouth sores (mucositis)
  • Diarrhea or constipation

General/Systemic Effects

  • Fatigue (often the most bothersome side effect)
  • Hair loss (alopecia)
  • Fever
  • Allergic reactions (more common with paclitaxel)

Other Possible Effects

  • Joint and muscle pain (myalgia/arthralgia)
  • Skin reactions at injection sites
  • Nail changes

Why This Combination Is Preferred

According to NCCN Guidelines, the carboplatin/paclitaxel regimen was compared to other chemotherapy combinations (like cisplatin/doxorubicin/paclitaxel) in clinical trials. The results showed:

  • Similar effectiveness in treating the cancer
  • Better tolerability - fewer severe side effects overall
  • Improved quality of life during treatment
  • Lower rates of certain toxicities like kidney damage and severe nausea

Important Context

The severity and duration of side effects vary significantly from person to person based on:

  • Your overall health and age
  • Kidney and liver function
  • Other medications you're taking
  • Genetic factors affecting drug metabolism
  • Dose intensity and number of cycles

Managing Side Effects

Your oncology team will:

  • Monitor blood counts regularly with lab tests
  • Prescribe medications to prevent/manage nausea
  • Assess for nerve damage at each visit
  • Adjust doses if severe side effects occur
  • Provide supportive care recommendations

Questions to Ask Your Healthcare Team

  1. Which side effects should I report immediately (versus managing at home)?
  2. What medications will you prescribe to prevent nausea and other side effects?
  3. How often will you check my blood counts during treatment?
  4. What signs of infection or bleeding should prompt me to call you?
  5. Are there any dietary changes or supplements that might help manage side effects?
  6. If I experience severe nerve damage, can we modify the treatment plan?
  7. How long do these side effects typically last after treatment ends?

Important Reminder

While these side effects can be challenging, they are generally manageable with proper medical support. The goal is to balance effective cancer treatment with maintaining your quality of life during therapy. Your oncology team has many strategies to help minimize side effects while you receive treatment.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about managing side effects during your specific treatment.


Sources:

  • NCCN Guidelines for Uterine Neoplasms (Version 1.2026) - Chemotherapy section for advanced/recurrent endometrial cancer
  • Referenced clinical trials: GOG 209 (Miller et al., 2020) and MITO end-2 trial (Lorusso et al., 2019)

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: